Cover Image
Market Research Report

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 361640
Published Content info 64 Pages
Delivery time: 1-2 business days
Price
Back to Top
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018
Published: October 16, 2018 Content info: 64 Pages
Description

Summary:

According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018'; Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of auto reactive T-cells.

The report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 3, 5 and 1 respectively. Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Autoimmune Disorders, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Solid Tumor, Stroke and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1711TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
    • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Celgene Corp
    • Medicenna Therapeutics Corp
    • Nektar Therapeutics
    • Philogen SpA
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
    • ALKS-4230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APT-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basiliximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basiliximab biobetter - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-92252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daclizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daromun - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDNA-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NARA-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKTR-358 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumors
      • Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
      • May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits
      • May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
      • Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
      • Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta
      • Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis
      • Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
      • Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage
      • Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting
      • Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
      • Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
      • Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
      • Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
      • Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Alkermes Plc, H2 2018
  • Pipeline by Celgene Corp, H2 2018
  • Pipeline by Medicenna Therapeutics Corp, H2 2018
  • Pipeline by Nektar Therapeutics, H2 2018
  • Pipeline by Philogen SpA, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top